[Transgenic animals].
Molecular biological technique has enabled us to create numerous transgenic animals characterized by enhanced or reduced expression of target gene products. These animal models are very useful not only to study the physiological roles of target gene products but also to evaluate the clinical usefulness of newly developed drugs and other therapeutic measures. Unfortunately, we still do not have a genetically engineered animal model that spontaneously develops acute coronary syndrome. However, there are several transgenic mice showing abnormal lipid metabolism and developing premature atherosclerosis. In this chapter, recent advance in the field of atherosclerotic animal models will be summarized.
Urasawa
K
K
Department of Cardiovascular Medicine, Hokkaido University School of Medicine.
Kitabatake
A
A
D000208:Acute Disease; D000818:Animals; D030801:Animals, Genetically Modified; D003324:Coronary Artery Disease; D003327:Coronary Disease; D004195:Disease Models, Animal; D051521:Fibroblast Growth Factor 5; D005346:Fibroblast Growth Factors / Q000235:genetics; D006801:Humans; D006949:Hyperlipidemias / Q000235:genetics; D050356:Lipid Metabolism; D051379:Mice; D008822:Mice, Transgenic; D018919:Neovascularization, Physiologic; D011817:Rabbits; D013577:Syndrome
C496449:FGF5 protein, human; C496450:Fgf5 protein, mouse; D051521:Fibroblast Growth Factor 5; D005346:Fibroblast Growth Factors